Maravai LifeSciences Holdings, Inc. is a life sciences company. The Company provides products that enables the development of drug therapies, diagnostics, vaccines and support research on human diseases. The Company's segments include Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. It also provides research products for labeling and detecting proteins in cells and tissue samples. Its products include CleanCap, messenger ribonucleic acid (mRNA) and oligonucleotide. The Biologics Safety Testing focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing spectrum. The Company provides ultra-pure nucleotides to customers in the diagnostics, pharma, genomics and research markets.
52 Week high
52 Week low
GlobeNewsWire • 2 days ago • MRVIMaravai LifeSciences Hosts 2023 Investor R&D Day
GlobeNewsWire • 12 days ago • MRVIMaravai LifeSciences Chief Innovation Officer Kate Broderick Named to 2023 PharmaVoice 100
GlobeNewsWire • 26 days ago • MRVIMaravai LifeSciences to Host 2023 Investor R&D Day
GlobeNewsWire • about a month ago • MRVICygnus Technologies Receives 2023 R&D 100 Award for MockV® RVLP Kit
GlobeNewsWire • about 2 months ago • MRVIMaravai LifeSciences Announces August 2023 Investor Conference Schedule
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.